title: Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study.
abstract: BACKGROUND
  Continuous infusion (CI) of recombinant FVIII (rFVIII) concentrates has been reported as an effective and safe method to achieve haemostasis during major surgeries or severe bleeding events. For more effective and safer CI, better understanding of in vivo recovery (IVR) and clearance (CL) issues is imperative.
  
  
  OBJECTIVE
  We investigated the following factors affecting IVR and CL using univariate and multivariate regression analyses during 47 CIs in 34 patients: rFVIII concentrate type, haemophilia severity, blood type, the presence of hepatitis C virus (HCV) or human immunodeficiency virus (HIV), age and body mass index (BMI).
  
  
  RESULTS
  The mean IVR was 1.64 ± 0.49 IU dL-1per IU kg-1, and the mean CL during CI was 3.56 ± 1.57 mL h-1kg-1. The univariate and multivariate regression analyses showed that the CL of octocog alfa was significantly lower than that of rurioctocog alfa (P = 0.043 and 0.0034, respectively). There was a significant difference in BMI in the univariate and multivariate regression analyses (P = 0.0403 and 0.0376, respectively).
  
  
  CONCLUSIONS
  This study indicated that CL during CI was potentially affected by the type of rFVIII concentrate used and BMI.
authors.affiliation: Department of Transfusion Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Suzuki
authors.affiliation: Biostatistics Section, Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Hirakawa
authors.affiliation: Department of Clinical Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kishimoto
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kanematsu
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kiyoi
authors.affiliation: Department of Transfusion Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Matsushita
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005169:Factor VIII / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007260:Infusion Pumps; D008875:Middle Aged; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D005169:Factor VIII
keywords: clearance; factor VIII; haemophilia A; in vivo recovery; pharmacokinetics